Wide Ranks

AMGN

Amgen Inc.

280.07

Top Statistics
Market Cap 150 B Forward PE 13.57 Revenue Growth 23.20 %
Current Ratio 1.32 Trailing PE 35.72 Earnings Growth 62.10 %
Profit Margins 13.00 % Peg Ratio Dividend Yield 3.21 %
Enterprice / EBITA 16.49 Enterprise / Revenue 6.21 Price To Sales Trailing12 Months 4.63
Profitability
Profit Margins 13.00 % Operating Margins 24.16 %
Balance Sheet
Total Cash 9 B Total Cash Per Share 16.76 Total Debt 60 B
Total Debt To Equity 802.42 Current Ratio 1.32 Book Value Per Share 14.00
All Measures
Return On Equity 0.5572 Total Debt 60 B Beta 0.5990
Last Split Date 943 M Fifty Two Week Low 257.80 Audit Risk 3
Target Mean Price 330.93 Short Percent Of Float 0.0183 Trailing Peg Ratio 200.93 %
Last Fiscal Year End 1 B Average Volume10days 5 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0025 Ebitda Margins 37.64 % Trailing PE 35.72
Most Recent Quarter 1 B Gmt Off Set Milliseconds -18000000 Fifty Day Average 313.58
Open 279.00 State CA Return On Assets 0.0460
Time Zone Short Name EST Board Risk 8 Trailing Eps 7.84
Day Low 278.00 Shares Outstanding 537 M Compensation Risk 2
Price Hint 2 Website https://www.amgen.com 52 Week Change 0.0387
Recommendation Key buy Quick Ratio 80.40 % Last Split Factor 2:1
Is_sp_500 True Profit Margins 13.00 % Debt To Equity 802.42
Fifty Two Week High 346.85 Enterprise To Revenue 6.21 Operating Cashflow 7 B
Five Year Avg Dividend Yield 295.00 % Market Cap 150 B Quote Type EQUITY
Industry Drug Manufacturers - General Ex Dividend Date 1 B Overall Risk 2
Long Name Amgen Inc. Current Ratio 1.32 Number Of Analyst Opinions 27
Governance Epoch Date 1 B Forward PE 13.57 Regular Market Volume 6 M
Short Ratio 412.00 % Message Board Id finmb_24816 Fax 805 447 1010
Shares Short Prior Month 9 M City Thousand Oaks Uuid 9376b97e-b428-3231-ba0b-142b20481cb4
Previous Close 280.01 First Trade Date Epoch Utc 424 M Book Value 14.00
Volume 6 M Price To Book 20.00 Total Cash Per Share 16.76
Total Revenue 32 B Shares Short Previous Month Date 1 B Target Median Price 335.00
Max Age 86400 Recommendation Mean 2.39 Sand P52 Week Change 0.3133
Operating Margins 24.16 % Last Dividend Value 2.25 Net Income To Common 4 B
Implied Shares Outstanding 537 M Average Daily Volume10 Day 5 M Total Cash 9 B
Revenue Per Share 60.64 Dividend Rate 9.00 Date Short Interest 1 B
Share Holder Rights Risk 1 Regular Market Previous Close 280.01 Target Low Price 200.00
Free Cashflow 4 B Dividend Yield 3.21 % Target High Price 405.00
Address1 One Amgen Center Drive Trailing Annual Dividend Rate 8.88 Average Volume 2 M
Earnings Quarterly Growth 63.60 % Forward Eps 20.67 Compensation As Of Epoch Date 1 B
Regular Market Day High 282.69 Day High 282.69 Shares Short 9 M
Regular Market Open 279.00 Industry Key drug-manufacturers-general Earnings Growth 62.10 %
Revenue Growth 23.20 % Shares Percent Shares Out 0.0182 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 True Zip 91320-1799
Payout Ratio 113.41 % Regular Market Day Low 278.00 Held Percent Institutions 0.8104
Current Price 280.07 Enterprise To Ebitda 16.49 Financial Currency USD
Trailing Annual Dividend Yield 3.17 % Gross Margins 60.59 % Industry Disp Drug Manufacturers - General
Country United States Float Shares 536 M Two Hundred Day Average 305.78
Ir Website http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome Enterprise Value 201 B Price To Sales Trailing12 Months 4.63
Last Dividend Date 1 B Ebitda 12 B Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.

The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.

The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co.

, Ltd.

for rocatinlimab development and commercialization; and BeiGene, Ltd.

for oncology products expansion and development.

Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.